Personalised strategies in cancer care are required to overcome the therapeutic challenges posed by variability between patients and disease subsets. To this end, enhanced precision tools must be developed to describe the molecular drivers of malignant proliferation. Such tools must also identify druggable targets and biomarkers in order to provide essential information regarding drug development and therapeutic outcome. Here we discuss how proteomics-based approaches provide a set of viable methodologies capable of delivering quantitative information throughout the main stages of personalised oncology and a ratiometric platform that delivers systems-wide methods for drug evaluation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.canlet.2016.01.049 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!